Aarey Drugs & Pharmaceuticals announces Q2 FY26 unaudited financial results; strong consolidated growth observed
Aarey Drugs & Pharmaceuticals announced unaudited Q2 FY26 results. Standalone net profit declined, but consolidated net profit and income saw significant growth, boosting EPS.
The announcement of unaudited quarterly and half-yearly financial results is a key event for investors. The substantial growth in consolidated revenue and a dramatic increase in consolidated net profit and EPS are very positive indicators that could significantly influence investor perception and stock performance, warranting a high impact.
The company reported a significant increase in consolidated total income from operations by 56.5% and a massive rise in consolidated net profit after tax to ₹3.58 crore for the quarter ended September 30, 2025, compared to ₹4.17 lakhs in the same quarter last year. Consolidated Basic EPS also saw a substantial increase from ₹0.09 to ₹1.95. While standalone net profit saw a decline, the strong consolidated performance indicates overall positive growth.
* Aarey Drugs & Pharmaceuticals Limited published its unaudited financial results for the quarter and half year ended 30th September 2025, as approved by the Board of Directors on 13th November 2025. * The results were published in 'Active Times' (English) and 'Mumbai Lakshadeep' (Marathi) newspapers on 15th November 2025, and are also available on the company's website. * Standalone Financial Highlights (Quarter Ended 30.09.2025 vs 30.09.2024): * Total income from operations (net) increased to ₹74.57 lakhs from ₹56.68 lakhs. * Net Profit after tax decreased to ₹0.89 lakhs from ₹3.11 lakhs. * Basic Earning Per Share (EPS) decreased to ₹0.02 from ₹0.07. * Consolidated Financial Highlights (Quarter Ended 30.09.2025 vs 30.09.2024): * Total income from operations (net) increased significantly to ₹17.49 crore (₹1,748.96 lakhs) from ₹11.17 crore (₹1,117.40 lakhs). * Net Profit after tax saw a massive increase to ₹3.58 crore (₹358.05 lakhs) from ₹4.17 lakhs. * Basic EPS rose substantially to ₹1.95 from ₹0.09.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.